Guest Writer
Companies have more options than ever before to access private capital across debt, minority or majority equity investments.
For the SPAC sponsor, without the benefit of the portfolio risk management of a venture fund, the risk-reward profile for a private biotech acquisition is not for the faint of heart.
The most significant downside of an increasingly large fund administrator is that customer service may fall by the wayside.
If a well-structured approach is taken, carve-out transactions can result in shortened TSA periods, accelerated ROI and win-win relationships, writes Paul Lennick of ContinuServe.
The question that continues to plague sponsors seeking to stabilize or enhance value creation is: How do we accurately diagnose a problem with PPMC performance?
Some ideas on how to compete in an industry whose number of active participants has more than doubled in the past ten years.
Advanced people-focused solutions implemented early in the investment lifecycle can mitigate risks of today’s virtual environment and offer a competitive edge in an aggressive market, writes Matt Brubaker, CEO, FMG Leading.
This year will continue to see flexible, de-risked deal structures.
The new model of distance learning has not only made traditional testing impractical, it’s exposed deep disparities.
Leading private funds are designing a robust governance process built on transparency, communication and independent advice.